Pregabalin Sandoz GmbH

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Sandoz GmbH

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

EpilepsyPregabalin Sandoz GmbH je označen kot adjunctive terapija pri odraslih z delni epileptični napadi z ali brez sekundarne posplošitev. Splošne Anksioznosti DisorderPregabalin Sandoz GmbH je primerna za zdravljenje Splošne Anksiozne Motnje (GAD) pri odraslih.

Product summary:

Revision: 16

Authorization status:

Umaknjeno

Authorization date:

2015-06-19

Patient Information leaflet

                                25
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl
Avstrija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/15/1012/001-010
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pregabalin Sandoz GmbH 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC {številka}
SN {številka}
NN {številka}
Zdravilo nima veā dovoljenja za promet
26
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOTI
1.
IME ZDRAVILA
Pregabalin Sandoz GmbH 25 mg trde kapsule
pregabalin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Sandoz
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
Zdravilo nima veā dovoljenja za promet
27
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI
ŠKATLA ZA VSEBNIK IN NALEPKA ZA VSEBNIK
1.
IME ZDRAVILA
Pregabalin Sandoz GmbH 25 mg trde kapsule
pregabalin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena trda kapsula vsebuje 25 mg pregabalina.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
200 trdih kapsul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
Uporabite v 6 mesecih od prvega odprtja.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Zdravilo nim
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
2
1.
IME ZDRAVILA
Pregabalin Sandoz GmbH 25 mg trde kapsule
Pregabalin Sandoz GmbH 50 mg trde kapsule
Pregabalin Sandoz GmbH 75 mg trde kapsule
Pregabalin Sandoz GmbH 100 mg trde kapsule
Pregabalin Sandoz GmbH 150 mg trde kapsule
Pregabalin Sandoz GmbH 200 mg trde kapsule
Pregabalin Sandoz GmbH 225 mg trde kapsule
Pregabalin Sandoz GmbH 300 mg trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Pregabalin Sandoz GmbH 25 mg trde kapsule
Ena trda kapsula vsebuje 25 mg pregabalina.
Pregabalin Sandoz GmbH 50 mg trde kapsule
Ena trda kapsula vsebuje 50 mg pregabalina.
Pregabalin Sandoz GmbH 75 mg trde kapsule
Ena trda kapsula vsebuje 75 mg pregabalina.
Pregabalin Sandoz GmbH 100 mg trde kapsule
Ena trda kapsula vsebuje 100 mg pregabalina.
Pregabalin Sandoz GmbH 150 mg trde kapsule
Ena trda kapsula vsebuje 150 mg pregabalina.
Pregabalin Sandoz GmbH 200 mg trde kapsule
Ena trda kapsula vsebuje 200 mg pregabalina.
Pregabalin Sandoz GmbH 225 mg trde kapsule
Ena trda kapsula vsebuje 225 mg pregabalina.
Pregabalin Sandoz GmbH 300 mg trde kapsule
Ena trda kapsula vsebuje 300 mg pregabalina.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trda kapsula
Pregabalin Sandoz GmbH 25 mg trde kapsule
Neprozorna pokrovček in telo blede rumenkasto-rjave barve, velikost
kapsule 4 (14,3 mm x 5,3 mm),
napolnjena s praškom bele do belkaste barve.
Pregabalin Sandoz GmbH 50 mg trde kapsule
Neprozorna pokrovček in telo svetlo rumene barve, velikost kapsule 3
(15,9 mm x 5,8 mm),
napolnjena s praškom bele do belkaste barve.
Pregabalin Sandoz GmbH 75 mg trde kapsule
Neprozoren pokrovček rdeče barve in neprozorno telo bele barve,
velikost kapsule 4 (14,3 mm x
5,3 mm), napolnjena s praškom bele do belkaste barve.
Zdravilo nima veā dovoljenja za promet
3
Pregabalin Sandoz GmbH 100 mg trde kapsule
Neprozorna pokrovček in telo blede rumenkasto-rjave barve, velikost
kapsule 4 (14,3 mm x 5,3 mm),
napolnjena s praškom bele do 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-10-2023
Public Assessment Report Public Assessment Report Bulgarian 12-10-2023
Patient Information leaflet Patient Information leaflet Spanish 12-10-2023
Public Assessment Report Public Assessment Report Spanish 12-10-2023
Patient Information leaflet Patient Information leaflet Czech 12-10-2023
Public Assessment Report Public Assessment Report Czech 12-10-2023
Patient Information leaflet Patient Information leaflet Danish 12-10-2023
Public Assessment Report Public Assessment Report Danish 12-10-2023
Patient Information leaflet Patient Information leaflet German 12-10-2023
Public Assessment Report Public Assessment Report German 12-10-2023
Patient Information leaflet Patient Information leaflet Estonian 12-10-2023
Public Assessment Report Public Assessment Report Estonian 12-10-2023
Patient Information leaflet Patient Information leaflet Greek 12-10-2023
Public Assessment Report Public Assessment Report Greek 12-10-2023
Patient Information leaflet Patient Information leaflet English 12-10-2023
Public Assessment Report Public Assessment Report English 12-10-2023
Patient Information leaflet Patient Information leaflet French 12-10-2023
Public Assessment Report Public Assessment Report French 12-10-2023
Patient Information leaflet Patient Information leaflet Italian 12-10-2023
Public Assessment Report Public Assessment Report Italian 12-10-2023
Patient Information leaflet Patient Information leaflet Latvian 12-10-2023
Public Assessment Report Public Assessment Report Latvian 12-10-2023
Patient Information leaflet Patient Information leaflet Lithuanian 12-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-10-2023
Public Assessment Report Public Assessment Report Lithuanian 12-10-2023
Patient Information leaflet Patient Information leaflet Hungarian 12-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 12-10-2023
Public Assessment Report Public Assessment Report Hungarian 12-10-2023
Patient Information leaflet Patient Information leaflet Maltese 12-10-2023
Public Assessment Report Public Assessment Report Maltese 12-10-2023
Patient Information leaflet Patient Information leaflet Dutch 12-10-2023
Public Assessment Report Public Assessment Report Dutch 12-10-2023
Patient Information leaflet Patient Information leaflet Polish 12-10-2023
Public Assessment Report Public Assessment Report Polish 12-10-2023
Patient Information leaflet Patient Information leaflet Portuguese 12-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 12-10-2023
Public Assessment Report Public Assessment Report Portuguese 12-10-2023
Patient Information leaflet Patient Information leaflet Romanian 12-10-2023
Public Assessment Report Public Assessment Report Romanian 12-10-2023
Patient Information leaflet Patient Information leaflet Slovak 12-10-2023
Public Assessment Report Public Assessment Report Slovak 12-10-2023
Patient Information leaflet Patient Information leaflet Finnish 12-10-2023
Public Assessment Report Public Assessment Report Finnish 12-10-2023
Patient Information leaflet Patient Information leaflet Swedish 12-10-2023
Public Assessment Report Public Assessment Report Swedish 12-10-2023
Patient Information leaflet Patient Information leaflet Norwegian 12-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 12-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 12-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 12-10-2023
Patient Information leaflet Patient Information leaflet Croatian 12-10-2023
Public Assessment Report Public Assessment Report Croatian 12-10-2023

Search alerts related to this product